{"entity":{"id":"nct07692750","kind":"trial","name":"IBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer","aka":[],"tldr":"A phase 1/2 trial of IBI343, capecitabine and cAPOX (capecitabine, oxaliplatin) in pancreatic cancer, run by Zhejiang Cancer Hospital, now recruiting.","summary":"IBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer is a phase 1/2, interventional study registered as NCT07692750 by Zhejiang Cancer Hospital, with a registry enrolment figure of 56 participants, started 2025-04-30 and due to reach its primary completion in 2027-06-30. Interventions recorded: IBI343+ capecitabine; IBI343+Capecitabine+oxaliplatin. Conditions listed: Advanced Pancreatic Cancer. Primary outcome: Objective Response Rate (ORR) according to RECIST v1.1; Adverse Event, Treatment-Emergent Adverse Event, Adverse Event of Special Interest, Serious Serious Adverse EventChanges in laboratory tests, physical examinations, vital signs, etc., incidence, and correlation with experimental drugs. Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07692750","url":"https://clinicaltrials.gov/study/NCT07692750"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["metastatic-pdac"],"sections":[],"technologies":["adc","cytotoxic-chemotherapy"],"targets":[],"drugs":["ibi343","capecitabine","capox"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07692750","phase":"1/2","setting":"A Phase Ib/II Study to Evaluate the Safety, Tolerability and Efficacy of IBI343 in Combination With Chemotherapy in Subjects With Advanced Pancreatic Cancer","sponsor":"Zhejiang Cancer Hospital","enrolled":56,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07692750/","neighbours":{"cancer":[{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"drug":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"capox","kind":"drug","name":"CAPOX (capecitabine, oxaliplatin)","route":"/drugs/capox/"},{"id":"ibi343","kind":"drug","name":"IBI343","route":"/drugs/ibi343/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}